AN2 Therapeutics Inc (ANTX) 銘柄情報

Open market purchase always welcomed :)..even if tiny 😜

Common Stock-CEO
11/18/2024
50,000
A
$0.9994
1,065,76

ANTX MINI BIO BEAST

I haven’t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)… as you know, any biotech is risky but I like the odds on this one and starter position is small for now…I did copy this from release that I found appealing:

Boron Chemistry Pipeline

Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

Global Health

In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.

NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?

Picked up a bit more down here at $1ish, you still in??

ANTX new 52 week low

ANTX under $3

looking good

ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783

FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE

THE FOLLOWING FROM THE 3/28 NEWS:

“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE

Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE

Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE

ANTX new 52 week low

ANTX new 52 week low

ANTX new 52 week low